NCT05177770

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Coherus Oncology, Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Detailed description

This is a phase 2, open-label, safety and preliminary efficacy trial in patients with mCRPC using the combination of SRF617, etrumadenant (AB928), and zimberelimab (AB122).

Conditions

• Metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Interventions

Type	Name	Description
DRUG	SRF617	SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.
DRUG	etrumadenant	Etrumadenant is an A2aR and A2bR antagonist.
DRUG	zimberelimab	Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Timeline

• Start date: 2022-01-17
• Primary completion: 2023-04-05
• Completion: 2023-04-05
• First posted: 2022-01-05
• Last updated: 2025-05-08
• Results posted: 2024-05-17

Locations

9 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study